Lyell Immunopharma, Inc.
$24.89
▲
1.92%
2026-04-21 08:00:02
www.lyell.com
NMS: LYEL
Explore Lyell Immunopharma, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$559.6 M
Current Price
$24.89
52W High / Low
$45 / $7.65
Stock P/E
—
Book Value
$11.68
Dividend Yield
—
ROCE
-69.37%
ROE
-86.98%
Face Value
—
EPS
$-16.06
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
—
Beta
-0.07
Debt / Equity
20.55
Current Ratio
5.28
Quick Ratio
5.28
Forward P/E
-26.65
Price / Sales
14,508.96
Enterprise Value
$325.62 M
EV / EBITDA
-1.74
EV / Revenue
9,045.03
Rating
None
Target Price
$32.5
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | eXoZymes, Inc. | $10.66 | — | $89.88 M | — | -220.6% | -1.33% | $18.4 / $7.08 | $0.4 |
| 2. | Kalaris Therapeutics, Inc. | $6.6 | — | $132.49 M | — | -41.2% | -3.08% | $11.88 / $2.14 | $3.44 |
| 3. | Inhibikase Therapeutics, Inc. | $1.81 | — | $238.98 M | — | -30.85% | -36.04% | $2.37 / $1.33 | $1.02 |
| 4. | PolyPid Ltd. | $4.69 | — | $89.5 M | — | -226.3% | -3.66% | $5.12 / $2.44 | $0.6 |
| 5. | Bio Green Med Solution, Inc. | $1.19 | — | $6.54 M | 0.93% | 552.16% | -1.28% | $100.8 / $0.73 | $1.27 |
| 6. | ProQR Therapeutics N.V. | $1.84 | — | $206.51 M | — | -54.09% | -61.17% | $3.1 / $1.1 | $0.54 |
| 7. | Recursion Pharmaceuticals, Inc. | $3.69 | — | $1.95 B | — | -48.86% | -59.54% | $7.18 / $2.8 | $2.14 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0.01 M | 0.01 M | 0.01 M | 0.01 M | 0.01 M | — |
| Operating Profit | -61.31 M | -37.25 M | -45.7 M | -57.37 M | -62.67 M | — |
| Net Profit | -140.72 M | -38.85 M | -42.68 M | -52.2 M | -191.94 M | — |
| EPS in Rs | -6.03 | -1.67 | -1.83 | -2.24 | -8.23 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0.04 M | 0.06 M | 0.13 M | 84.68 M |
| Operating Profit | -201.63 M | -220.27 M | -247.01 M | -187.06 M |
| Net Profit | -274.45 M | -342.99 M | -234.63 M | -183.12 M |
| EPS in Rs | -11.76 | -14.7 | -10.06 | -7.85 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 340.05 M | 490.86 M | 750.03 M | 937.56 M |
| Total Liabilities | 91.85 M | 108.03 M | 95.08 M | 104.31 M |
| Equity | 248.2 M | 382.82 M | 654.95 M | 833.25 M |
| Current Assets | 260.94 M | 379.59 M | 554.69 M | 651.29 M |
| Current Liabilities | 49.41 M | 53.79 M | 34.52 M | 37.03 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -150.02 M | -162.39 M | -163.69 M | -169.56 M |
| Investing CF | 54.1 M | 122.42 M | 184.05 M | -11.54 M |
| Financing CF | 50.41 M | 1.33 M | 1.74 M | 10.63 M |
| Free CF | -150.8 M | -162.86 M | -166.38 M | -193.83 M |
| Capex | -0.78 M | -0.46 M | -2.69 M | -24.28 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | -40.98% | -53.08% | -99.85% | — |
| Earnings Growth % | 19.98% | -46.18% | -28.13% | — |
| Profit Margin % | -762355.56% | -562285.25% | -180486.15% | -216.24% |
| Operating Margin % | -560080.56% | -361104.92% | -190006.15% | -220.89% |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -528027.78% | -328922.95% | -174429.23% | -199.61% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-06-02 | 1:0.05 |